185750.KS
Chong Kun Dang Pharmaceutical Corp.
KSC · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 68,200.00
−1.59%Year over year
Reported trailing growth
- Revenue
- +7.1%
- EBITDA
- -42.8%
- EBIT
- +12.0%
- EPS
- +26.0%
- Free cash flow
- -27.8%
- Operating cash flow
- +5718.0%
Forward estimates
Based on analyst estimates
- Revenue
- +7.8%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +4.4%
- EBITDA
- -3.0%
- EBIT
- -9.8%
- Net income
- -1.3%
- EPS
- -3.8%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026